Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease

Clinical Physiology and Functional Imaging

Volumn 39, Issue 2, 2019, Pages 122-127

  Rix, Iben ^a   Steen Pedersen, Julie ^a   Storgaard, Heidi ^a   Gluud, Lise Lotte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cardiovascular disease; dipeptidyl peptidase 4 inhibitors; glitazones; glucagon like peptide 1 receptor agonists; Non alcoholic fatty liver disease; review; sodium glucose cotransporter 2 inhibitors

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

APOPTOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EVALUATION; CLINICAL OUTCOME; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; HEART DISEASE; HEART FAILURE; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOTOXICITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME; BLOOD; CARDIOVASCULAR DISEASE; METABOLIC SYNDROME X; PROTECTION; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 85047660397     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/cpf.12526     Document Type: Review

References (56)

1. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2015); 149: 389–397 e310.
2. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (2016); 387: 679–690.
3. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens (2014); 8: 262–275 e269.
4. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008); 117: 2340–2350.
5. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005); 42: 44–52.
6. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS ONE (2014); 9: e87488.
7. Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J (2012); 33: 1190–1200.
8. Bonci E, Chiesa C, Versacci P, et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed Res Int (2015); 2015: 213737.
9. Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am (2016); 45: 639–652.
10. Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol (2016); 65: 369–376.
11. Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) (2017); 96: e8179.
12. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005); 115: 1343–1351.
13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005); 366: 1279–1289.
14. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (2015); 61: 1547–1554.
15. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol (2016); 64: 1388–1402.
16. European Medicines Agency. European public assessment reports; 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125.23-01
17. Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation (1997); 96: 2520–2525.
18. Geisler CE, Renquist BJ. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. J Endocrinol (2017); 234: R1–R21.
19. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015); 373: 232–242.
20. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev (2007); 87: 1409–1439.
21. Joy TR, McKenzie CA, Tirona RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol (2017); 23: 141–150.
22. Junker AE, Gluud L, Holst JJ, et al. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med (2016); 279: 485–493.
23. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol (2013); 48: 434–441.
24. Liu R, Li L, Chen Y, et al. Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis. Ann Med (2014); 46: 664–671.
25. Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications (2015); 29: 1295–1303.
26. Luna-Luna M, Medina-Urrutia A, Vargas-Alarcon G, et al. Adipose tissue in metabolic syndrome: onset and progression of atherosclerosis. Arch Med Res (2015); 46: 392–407.
27. Mantovani A, Ballestri S, Lonardo A, et al. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci (2016); 61: 1246–1267.
28. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001); 50: 1844–1850.
29. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med (2016a); 375: 1834–1844.
30. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med (2016b); 375: 311–322.
31. Matikainen N, Bogl LH, Hakkarainen A, et al. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care (2014); 37: 242–251.
32. Moller S, Bendtsen F. NAFLD: cardiovascular complications of NAFLD–they do matter. Nat Rev Gastroenterol Hepatol (2015); 12: 434–436.
33. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia (2012); 55: 885–904.
34. Musso G, Cassader M, Cohney S, et al. Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities. Diabetes Care (2016); 39: 1830–1845.
35. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia (1986); 29: 46–52.
36. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and in cardiovascular and renal events type 2 diabetes. N Engl J Med (2017); 377: 644–657.
37. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis (2013); 230: 258–267.
38. Petta S, Argano C, Colomba D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol (2015); 62: 928–933.
39. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med (2015); 373: 2247–2257.
40. Puchakayala BK, Verma S, Kanwar P, et al. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol (2015); 7: 2610–2618.
41. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010); 53: 372–384.
42. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013); 369: 1317–1326.
43. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open (2016); 6: e009417.
44. Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE (2016); 11: e0166125.
45. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract (2015); 110: 26–37.
46. US Food and Drug Administration. FDA Approved Drug Products. 2017. www.fda.gov/drugsatfda.23-01
47. Vanni E, Marengo A, Mezzabotta L, et al. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis (2015); 35: 236–249.
48. VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology (2015); 62: 773–783.
49. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012); 344: d7771.
50. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013); 369: 1327–1335.
51. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) (2012); 91: 319–327.
52. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (2016); 64: 73–84.
53. Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology (2017); doi: 10.1002/hep.29724. [Epub ahead of print].
54. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab (2016); 18: 783–794.
55. Zhong J, Maiseyeu A, Davis SN, et al. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res (2015); 116: 1491–1504.
56. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med (2015); 373: 2117–2128.